Drug Trial Radar · NCT07131202
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Jan 8, 2026
Primary completion
Dec 5, 2026
Study completion Dec 5, 2028
Sponsor
- Lead sponsor
- Suzhou Forlong Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, Phase Ib/II clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of FL115 in combination with the anti-PD-1 monoclonal antibody, in participants with advanced solid tumors. All enrolled participants will receive FL115 and Sintilimab via intravenous (IV) infusion. Treatment will continue until disease progression (excluding pseudoprogression), unacceptable toxicity, or other protocol-specified criteria for study or treatment discontinuation, whichever occurs first. The study consists of two parts: a dose-escalation phase (Phase Ib) and a cohort-expansion phase (Phase II). The Phase 2 part will explore the preliminary efficacy and safety of the combination therapy in patients with advanced solid tumors across different tumor types.
Conditions
- Advanced Solid Tumors
Interventions
FL115+PD-1Drug
Combined treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and ToleranceTime frame: From screening to 30 days after last dose
- MTD/RDETime frame: through study completion, an average of 15 months
- ORRTime frame: About 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.